Grand Cayman, Caribbean
Whatsapp +33758673528 e-mail: head_office@nbscience.com
Stem Cell Therapy Clinic is located on Seven Mile Beach in Grand Cayman, a small island paradise in the Caribbean. The Cayman Islands is an English-speaking British Overseas Territory and hosts over 2 million tourists a year. There are many direct flights to Grand Cayman from major cities in the U.S. and Europe.
About Stem Cells laboratory
Scalable Manufacturing
under strict environmental and laboratory controls in accordance with cGMP.
cGMP compliant and CLIA certified, with a QMS that is globally recognized as ISO 9001:2015 and ISO 13485:2016 certified. Operated a highly regulated, FDA-compliant commercial biologics manufacturing facility for several years and is cGMP compliant, ISO9001 Certified, ISO13485 Certified, CLIA Certified and FDA registered. All clinical manufacturing occurs in a certified sterile clean room with extensive and advanced testing to assure the absence of contamination.
Innovative biotechnology company focused on developing Wharton’s jelly-derived cell therapies and targeting autoimmune diseases and inflammatory disorders.
About Cayman islands
The Cayman Islands are an overseas territory of the United Kingdom in the Caribbean Sea, comprising the islands of Grand Cayman, Little Cayman, and Cayman Brac, situated about 450 miles (724 km) southwest of Miami, FL, United States. The islands are the outcroppings of a submarine mountain range that extends northeastward from Belize to Cuba. The capital is George Town, on Grand Cayman and the main airport is named Owen Roberts International (GCM).
The Cayman Islands are a safe and popular medical tourism / vacation destination. The high level of safety is one of the reasons why so many families visit Grand Cayman every year. Over 2-million tourists visit the Cayman Islands every year, and virtually no one has any issues.
A Visa is not required for US, Canadian and European visitors, however you will require a passport to enter the country.
Is your facility licensed?
It is fully licensed healthcare facility that has been authorized to operate by the government of the Cayman Islands. As a British Overseas Territory, healthcare regulations are extremely strict, on par with the US, UK, and EU. Additionally, entire medical staff is fully registered and licensed, and stem cell protocols are IRB reviewed and approved by a board in the United States.
IRB-approved protocol consists of a two-day period that involves the intravenous (IV) transplant of 300 million culturally expanded human umbilical cord tissue-derived adult mesenchymal stem cells (MSCs).
1) The treatment protocol involves the systemic administration of a culturally expanded mesenchymal stem cell product – which is not authorized in the United States. The dosage is standardized to 300 million mesenchymal stem cells per patient split into 6 separate vials of 50 million cells to ensure smooth administration and prevent any cell clumping.
2) The facility is required to submit efficacy data every year to its IRB to continue enrolling patients. The clinic is directly regulated by the Cayman Islands Government, which has strict criteria that must be followed to conduct patient-funded clinical trials.
3) Rather than making direct claims to be able to treat specific conditions – rather the team utilizes information on the website as statistical tools using data collected from third-party peer-reviewed studies.
4) Protocols are highly regulated and patient safety is of utmost importance. The mesenchymal stem cells are ethically sourced from AATB certified, US-donated, full-term human umbilical cords and processed in award-winning partner medical laboratory located in the USA, which is fully FDA registered, cGMP compliant, ISO 9001, and ISO 13485 certified.
The cells are tested to ISCT standards for viability to ensure they meet minimum QA requirements multiple times before treatment. To ensure cell safety, we conduct advanced therapy testing for sterility, endotoxins, mycoplasma, HIV-1/HIV-2, Hepatitis B, Hepatitis C, and Syphilis on the cells post expansion as well as the donated umbilical cords.
Confirmation of identity (URMC Flow Cytometry) testing is also conducted to ensure post-thaw viability, and MSC phenotype expression (CD73+, CD90+, CD105, etc.). This ensures a standardized cell product which helps the medical team provide further insight into treatment efficacy
5) Is transparent with any inquiries concerning treatment protocols, efficacy data, and cell products, the facility and staff never aim to mislead anyone or make false claims on the website that cannot be backed up with real data.
6) Treatment protocol is designed in such a way as to ensure patient safety – this would not be possible if there were not hundreds of peer-reviewed studies that came before ours that showcased the safety of mesenchymal stem cells derived from umbilical cord tissue when used in a clinical setting.
NOTE: This post is intended to provide general information about regenerative medicine, and related areas. All content provided in this blog, website, or any linked materials, including text, graphics, images, patient outcomes, and information, are not intended and should not be considered or used as a substitute for medical advice, diagnosis, or treatment. Please always consult with a professional and certified healthcare provider to discuss if a treatment is right for you.
Whatsapp +33758673528 e-mail: head_office@nbscience.com
Seven Mile Beach Grand Cayman (2022) – All You Need To Know
Recommended hotel:
The Ritz-Carlton *****, Grand Cayman
PO Box 32348 KY1-1209, Seven Mile Beach
Grand Cayman, KY1-1209 Cayman Islands
Articles about stem cell therapy :
(please contact Editor to get original articles)
ALS
ALS Pathogenesis and Therapeutic Approaches: The Role of Mesenchymal Stem Cells and Extracellular Vesicles
ALS
Mechanisms underlying the protective effects of mesenchymal stem cell-based therapy
ALS
Mesenchymal Stromal Cell Therapies for Neurodegenerative Diseases
ALS
NurOwn, phase 2, randomized, clinical trial in patients with ALS
ALS
Therapeutic Potential of Mesenchymal Stromal Cells and MSC Conditioned Medium in Amyotrophic Lateral Sclerosis (ALS) – In Vitro Evidence from Primary Motor Neuron Cultures, NSC-34 Cells, Astrocytes and Microglia
ALS
Phase I Trial of Repeated Intrathecal Autologous Bone Marrow-Derived Mesenchymal Stromal Cells in Amyotrophic Lateral Sclerosis
ALS
Mesenchymal Stem Cells: A Potential Therapeutic Approach for Amyotrophic Lateral Sclerosis?
ALS
Neuroprotective Potential of Cell-Based Therapies in ALS: From Bench to Bedside
Alzheimer’s
Regenerative Stem Cell Therapy for Neurodegenerative Diseases: An Overview
Alzheimer’s
Stem cell therapy for Alzheimer’s disease
Alzheimer’s
Alzheimer’s Disease and Stem Cell Therapy
Alzheimer’s
Immunomodulatory role of mesenchymal stem cells in Alzheimer’s disease
Alzheimer’s
Stem cell therapies for Alzheimer’s disease is it time?
Alzheimer’s
Stem cell therapy in Alzheimer’s disease: possible benefits and limiting drawbacks
Alzheimer’s
Stem Cells as Potential Targets of Polyphenols in Multiple Sclerosis and Alzheimer’s Disease
Alzheimer’s
Stem Cell Treatment for Alzheimer’s Disease
Alzheimer’s
Mesenchymal Stromal Cell Therapies for Neurodegenerative Diseases
Asthma
Small extracellular vesicles derived from human MSCs prevent allergic airway inflammation via immunomodulation on pulmonary macrophages
Asthma
Mesenchymal Stem Cells Recruit CCR2+ Monocytes to Suppress Allergic Airway Inflammation
Autoimmune
Immunoregulation by Mesenchymal Stem Cells: Biological Aspects and Clinical Applications
Autoimmune
Human umbilical cord mesenchymal stem cells for psoriasis: a phase 1/2a, single-arm study
Autoimmune
Evaluation of the Therapeutic Potential of Mesenchymal Stem Cells (MSCs) in Preclinical Models of Autoimmune Diseases
COPD
Preclinical Studies of Mesenchymal Stem Cell (MSC) Administration in Chronic Obstructive Pulmonary Disease (COPD): A Systematic Review and Meta-Analysis
COPD
Human umbilical cord mesenchymal stem cell-derived extracellular vesicles ameliorate airway inflammation in a rat model of chronic obstructive pulmonary disease (COPD)
COPD
Mesenchymal stromal cell therapy in COPD: from bench to bedside
COPD
Mesenchymal stem cell therapy in lung disorders: pathogenesis of lung diseases and mechanism of action of mesenchymal stem cell
COPD
Stem cell therapy in chronic obstructive pulmonary disease. How far is it to the clinic?
COPD
Paracrine effects and heterogeneity of marrow-derived stem/progenitor cells: relevance for the treatment of respiratory diseases
COPD
Mesenchymal Stem Cell Administration in Patients with Chronic Obstructive Pulmonary Disease: State of the Science
COPD
Can Youthful Mesenchymal Stem Cells from Wharton’s Jelly Bring a Breath of Fresh Air for COPD?
COPD
Mesenchymal stem cells and immunomodulation: current status and future prospects
COPD
Stem cell therapies for chronic obstructive pulmonary disease: current status of pre-clinical studies and clinical trials
COPD
Allogeneic umbilical cord-derived mesenchymal stem cell transplantation for treating chronic obstructive pulmonary disease: a pilot clinical study
COVID-19
Mesenchymal stem cells derived from perinatal tissues for treatment of critically ill COVID-19-induced ARDS patients: a case series
COVID-19
Promising role for mesenchymal stromal cells in coronavirus infectious disease-19 (COVID-19)-related severe acute respiratory syndrome?
COVID-19
Taming of Covid-19: potential and emerging application of mesenchymal stem cells
COVID-19
Therapeutic implications of mesenchymal stem cells in acute lung injury/acute respiratory distress syndrome
COVID-19
Taming of Covid-19: potential and emerging application of mesenchymal stem cells
COVID-19
Rationale for the clinical use of adipose-derived mesenchymal stem cells for COVID-19 patients
COVID-19
Stem cell therapy for COVID-19 and other respiratory diseases: Global trends of clinical trials
COVID-19
Human placenta-derived mesenchymal stem cells transplantation in patients with acute respiratory distress syndrome (ARDS) caused by COVID-19 (phase I clinical trial): safety profile assessment
Chronic Inflammation
Immune modulation by mesenchymal stem cells
Chronic Inflammation
Shattering barriers toward clinically meaningful MSC therapies
Crohn’s Disease
Mesenchymal Stem Cells for Perianal Crohn’s Disease
Crohn’s Disease
Umbilical Cord Mesenchymal Stem Cell Treatment for Crohn’s Disease: A Randomized Controlled Clinical Trial
Crohn’s Disease
Mesenchymal stem/stromal cells as a valuable source for the treatment of immune-mediated disorders
Crohn’s Disease
Mesenchymal stromal cells: clinical challenges and therapeutic opportunities
Crohn’s Disease
Efficacy of stem cells therapy for Crohn’s fistula: a meta-analysis and systematic review
Crohn’s Disease
Ex vivo immunosuppressive effects of mesenchymal stem cells on Crohn’s disease mucosal T cells are largely dependent on indoleamine 2,3-dioxygenase activity and cell-cell contact
Crohn’s Disease
Expanded allogeneic adipose-derived mesenchymal stem cells (Cx601) for complex perianal fistulas in Crohn’s disease: a phase 3 randomised, double-blind controlled trial
Diabetes
Current Status of Stem Cell Treatment for Type I Diabetes Mellitus
Diabetes
Stem cells as a potential therapy for diabetes mellitus: a call-to-action in Latin America
Diabetes
Mesenchymal stem cells: Stem cell therapy perspectives for type 1 diabetes
Diabetes
Applicability of adipose-derived mesenchymal stem cells in treatment of patients with type 2 diabetes
Diabetes
Mesenchymal Stem Cells as New Therapeutic Approach for Diabetes and Pancreatic Disorders
Diabetes
Clinical efficacy on glycemic control and safety of mesenchymal stem cells in patients with diabetes mellitus: Systematic review and meta-analysis of RCT data
Diabetes
Therapeutic Potential of Mesenchymal Stem Cells for Diabetes
Diabetes
Regenerative Therapy of Type 1 Diabetes Mellitus: From Pancreatic Islet Transplantation to Mesenchymal Stem Cells
Diabetes
Immunomodulation by Mesenchymal Stem Cells
Diabetes
Therapeutic Potential of Wharton’s Jelly Mesenchymal Stem Cells for Diabetes: Achievements and Challenges
Diabetes
Regenerative and Transplantation Medicine: Cellular Therapy Using Adipose Tissue-Derived Mesenchymal Stromal Cells for Type 1 Diabetes Mellitus
Diabetes
Identifying the Therapeutic Significance of Mesenchymal Stem Cells
Diabetes
Comparison of therapeutic effects of mesenchymal stem cells from umbilical cord and bone marrow in the treatment of type 1 diabetes
Fibromyalgia
Application of Adult and Pluripotent Stem Cells in Interstitial Cystitis/Bladder Pain Syndrome Therapy: Methods and Perspectives
Heart Failure
Rebuilding the Damaged Heart: Mesenchymal Stem Cells, Cell-Based Therapy, and Engineered Heart Tissue
Heart Failure
Allogeneic mesenchymal stem cells restore cardiac function in chronic ischemic cardiomyopathy via trilineage differentiating capacity
Heart Failure
Rebuilding the Damaged Heart: Mesenchymal Stem Cells, Cell-Based Therapy, and Engineered Heart Tissue
Heart Failure
Mesenchymal Stem Cells in Cardiology
Heart Failure
Transplantation of mesenchymal stem cells for prevention of acute myocardial infarction induced heart failure: study protocol of a phase III randomized clinical trial (Prevent-TAHA8)
Immunomodulation
Mesenchymal stem cells and immunomodulation: current status and future prospects
Immunomodulation
Human mesenchymal stem cells modulate allogeneic immune cell responses
Kidney Disease
Stem cell-based treatment of kidney diseases
Kidney Disease
Stem/progenitor cell in kidney: characteristics, homing, coordination, and maintenance
Kidney Disease
Safety and tolerability of autologous bone marrow mesenchymal stromal cells in ADPKD patients
Kidney Disease
Stem cells: a potential treatment option for kidney diseases
Kidney Disease
Potential and Therapeutic Efficacy of Cell-based Therapy Using Mesenchymal Stem Cells for Acute/chronic Kidney Disease
Kidney Disease
Mesenchymal stem cells and extracellular vesicles in therapy against kidney diseases
Kidney Disease
Stem/Stromal Cells for Treatment of Kidney Injuries With Focus on Preclinical Models
Kidney Disease
Mesenchymal Stem Cell Therapy for Diabetic Kidney Disease: A Review of the Studies Using Syngeneic, Autologous, Allogeneic, and Xenogeneic Cells
Kidney Disease
The therapeutic potential of Camel Wharton jelly mesenchymal stem cells (CWJ-MSCs) in canine chronic kidney disease model
Liver Disease
Stem Cell-Based Therapies for Liver Diseases: An Overview and Update
Liver Disease
Pre‐treatments enhance the therapeutic effects of mesenchymal stem cells in liver diseases
Liver Disease
Progress in mesenchymal stem cell–based therapy for acute liver failure
Liver Disease
Stem cell transplantation for treating liver diseases: progress and remaining challenges
Liver Disease
Therapeutic efficiency of bone marrow-derived mesenchymal stem cells for liver fibrosis: A systematic review of in vivo studies
Liver Disease
Systematic review: the effects of autologous stem cell therapy for patients with liver disease
Liver Disease
Mesenchymal stem cells-based therapy in liver diseases
Lupus
Allogeneic Mesenchymal Stem Cell Transplantation in Severe and Refractory Systemic Lupus Erythematosus: 4 Years of Experience
Lupus
Umbilical cord mesenchymal stem cell transplantation in severe and refractory systemic lupus erythematosus
Lupus
Additive Therapeutic Effects of Mesenchymal Stem Cells and IL-37 for Systemic Lupus Erythematosus
Lupus
Mesenchymal stem cell therapy induces FLT3L and CD1c+ dendritic cells in systemic lupus erythematosus patients
Lupus
Allogeneic Mesenchymal Stem Cell Transplantation in Severe and Refractory Systemic Lupus Erythematosus: 4 Years of Experience
Lupus
Umbilical cord mesenchymal stem cell transplantation in active and refractory systemic lupus erythematosus: a multicenter clinical study
Lupus
Human umbilical cord mesenchymal stem cells derived extracellular vesicles regulate acquired immune response of lupus mouse in vitro
Lyme Disease
Transplantation of Human Embryonic Stem Cells in Patients with Multiple Sclerosis and Lyme Disease
Lyme Disease
Single-photon emission tomography imaging in patients with Lyme disease treated with human embryonic stem cells
Mesenchymal Stem Cells
Mechanisms underlying the protective effects of mesenchymal stem cell-based therapy
Mesenchymal Stem Cells
Application of Mesenchymal Stem Cells in Inflammatory and Fibrotic Diseases
Mesenchymal Stem Cells
Mesenchymal stromal cells: sensors and switchers of inflammation
Mesenchymal Stem Cells
Extracellular vesicles derived from Wharton’s Jelly mesenchymal stem cells inhibit the tumor environment via the miR-125b/HIF1α signaling pathway
Multiple Sclerosis
The potential use of mesenchymal stem cells for the treatment of multiple sclerosis
Multiple Sclerosis
Mesenchymal stem/stromal cells as a valuable source for the treatment of immune-mediated disorders
Multiple Sclerosis
The Potential of Human Umbilical Cord-Derived Mesenchymal Stem Cells as a Novel Cellular Therapy for Multiple Sclerosis
Multiple Sclerosis
Mesenchymal Stem Cells in Multiple Sclerosis: Recent Evidence from Pre-Clinical to Clinical Studies
Multiple Sclerosis
Mesenchymal Stem Cells and Induced Pluripotent Stem Cells as Therapies for Multiple Sclerosis
Multiple Sclerosis
Clinical feasibility of umbilical cord tissue-derived mesenchymal stem cells in the treatment of multiple sclerosis
Multiple Sclerosis
Mesenchymal Stromal Cell Therapies for Neurodegenerative Diseases
Multiple Sclerosis
Safety and efficacy of stem cell therapy for treatment of neural damage in patients with multiple sclerosis
Multiple Sclerosis
IV/IT hUC-MSCs Infusion in RRMS and NMO: A 10-Year Follow-Up Study
Multiple Sclerosis
Autologous mesenchymal stem cells for the treatment of secondary progressive multiple sclerosis: an open-label phase 2a proof-of-concept study
Parkinson
Treatment of Parkinson’s Disease through Personalized Medicine and Induced Pluripotent Stem Cells
Parkinson’s
Pluripotent Stem Cell-based therapy for Parkinson’s disease: current status and future prospects
Parkinson’s
Mesenchymal stem cell therapy in Parkinson’s disease animal models
Parkinson’s
Role of Mesenchymal Stem Cells in Counteracting Oxidative Stress—Related Neurodegeneration
Parkinson’s
Cell replacement therapy for Parkinson’s disease: how close are we to the clinic?
Parkinson’s
Mesenchymal Stem Cells as a Source of Dopaminergic Neurons: A Potential Cell Based Therapy for Parkinson’s Disease
Parkinson’s
Mesenchymal Stromal Cell Therapies for Neurodegenerative Diseases
Parkinson’s Disease
Stem Cell-Based Therapies for Parkinson Disease
Parkinson’s Disease
A New Tool for Safety Evaluation and a Combination of Measures for Efficacy Assessment of Cotransplanting Human Allogenic Neuronal Stem Cells and Mesenchymal Stem Cells for the Treatment of Parkinson Disease: Protocol for an Interventional Study
Parkinson’s Disease
A New Tool for Safety Evaluation and a Combination of Measures for Efficacy Assessment of Cotransplanting Human Allogenic Neuronal Stem Cells and Mesenchymal Stem Cells for the Treatment of Parkinson Disease: Protocol for an Interventional Study
Parkinson’s Disease
Stem Cell-Based Therapies for Parkinson Disease
Parkinson’s Disease
Mesenchymal Stem Cells as a Cornerstone in a Galaxy of Intercellular Signals: Basis for a New Era of Medicine
Parkinson’s Disease
Allogeneic Bone Marrow–Derived Mesenchymal Stem Cell Safety in Idiopathic Parkinson’s Disease
Primary Biliary Cirrhosis
Pilot study of umbilical cord-derived mesenchymal stem cell transfusion in patients with primary biliary cirrhosis
Rheumatoid Arthritis
Human umbilical cord mesenchymal stem cell therapy for patients with active rheumatoid arthritis: safety and efficacy
Rheumatoid Arthritis
Mesenchymal Stem/Stromal Cells for Rheumatoid Arthritis Treatment: An Update on Clinical Applications
Rheumatoid Arthritis
Efficacy and Safety of Umbilical Cord Mesenchymal Stem Cell Therapy for Rheumatoid Arthritis Patients: A Prospective Phase I/II Study
Rheumatoid Arthritis
Recent Developments in Clinical Applications of Mesenchymal Stem Cells in the Treatment of Rheumatoid Arthritis and Osteoarthritis
Rheumatoid Arthritis
Multipotent Mesenchymal Stromal Cells in Rheumatoid Arthritis and Systemic Lupus Erythematosus; From a Leading Role in Pathogenesis to Potential Therapeutic Saviors?
Rheumatoid Arthritis
Therapeutic potential of human umbilical cord mesenchymal stem cells in the treatment of rheumatoid arthritis
Spinal Cord Injury
Treatment of spinal cord injury with mesenchymal stem cells
Stroke
Intravenous administration of auto serum-expanded autologous mesenchymal stem cells in stroke
Stroke
Stem Cell Transplantation Therapy for Multifaceted Therapeutic Benefits after Stroke
Stroke
Neuroinflammation as a target for treatment of stroke using mesenchymal stem cells and extracellular vesicles
Stroke
Stem Cell Therapy for Abrogating Stroke-Induced Neuroinflammation and Relevant Secondary Cell Death Mechanisms
Stroke
Autologous Mesenchymal Stem Cells in Chronic Stroke
Stroke
A Long‐Term Follow‐Up Study of Intravenous Autologous Mesenchymal Stem Cell Transplantation in Patients With Ischemic Stroke
Stroke
Efficacy of stem cell-based therapies for stroke
Stroke
Recent Advances in Cell-Based Therapies for Ischemic Stroke
Traumatic Brain Injury
The neuroprotection of hypoxic adipose tissue-derived mesenchymal stem cells in experimental traumatic brain injury
Traumatic Brain Injury
Mesenchymal stem cell therapy alleviates the neuroinflammation associated with acquired brain injury
Traumatic Brain Injury
Mesenchymal Stem Cells in the Treatment of Traumatic Brain Injury
Traumatic Brain Injury
Cell-Based therapy for traumatic brain injury
Traumatic Brain Injury
Genetically Modified Mesenchymal Stem Cells: The Next Generation of Stem Cell-Based Therapy for TBI
Traumatic Brain Injury
Mesenchymal Stem Cells of Dental Origin-Their Potential for Anti-inflammatory and Regenerative Actions in Brain and Gut Damage
Disclaimer: Stem cell therapy is a great alternative therapy but offers no guarantees and is not promoted as a cure. This is similar to many other conventional medical treatments. A complete review of the patient’s medical history is required to determine eligibility and approval for stem cell therapy. All personal information provided is for internal and medical use with medical providers only. Treatments are not conducted in offices or in the UK. All cellular therapies are conducted in Europe or Grand Cayman , as it is regulated by the Ministry of Health, COFEPRIS and other local authorities. All treatments are performed within the legal limits and regulatory framework for the country in which the specific medical provider practices.
